Physician profile
David L Hicks
NPI 1093904815
$33,272.42
in general payments reported to CMS, 2019-2025
69 companies · $5,387 in 2025
The $5,387 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,933 · 2020: $4,115 · 2021: $5,995 · 2022: $4,546 · 2023: $4,817 · 2024: $5,480 · 2025: $5,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,450.54 |
| Education | $233.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,537.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,387.54 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Otsuka America Pharmaceutical, INC. | $1,730.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $1,671.95 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,562.31 | 2019-2025 | Trelegy Ellipta, Benlysta, Nucala |
| Biohaven Pharmaceuticals, INC. | $1,489.28 | 2020-2021 | |
| Pfizer INC. | $1,413.59 | 2019-2025 | |
| Axsome Therapeutics, INC. | $1,400.68 | 2022-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $1,272.89 | 2019-2025 | |
| Lilly USA, LLC | $1,078.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,038.06 | 2019-2025 | Jardiance |
| Indivior INC. | $912.76 | 2019-2025 | Sublocade |
| Amgen INC. | $906.03 | 2019-2025 | Repatha, Evenity, Otezla |
| Harmony Biosciences LLC | $847.92 | 2020-2025 | Wakix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $801.02 | 2019-2025 | Xifaxan |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $763.34 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Welch Allyn | $733.56 | 2020 | |
| Allergan, INC. | $732.65 | 2019-2020 | |
| Alkermes, INC. | $613.44 | 2021-2025 | Aristada, Lybalvi |
| Esperion Therapeutics, INC. | $591.85 | 2020-2025 | Nexletol, Nexlizet |
| Corcept Therapeutics | $569.33 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $545.52 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $479.11 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $370.74 | 2019-2024 | Glassia, Takhzyro |
| Kowa Pharmaceuticals America, INC. | $326.22 | 2022-2025 | Zoryve, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $323.04 | 2022 | |
| Neurocrine Biosciences, INC. | $318.50 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $310.79 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $246.69 | 2019-2023 | Verquvo |
| Currax Pharmaceuticals LLC | $230.84 | 2022-2024 | Contrave, Nexletol, Nexlizet |
| Ucb, INC. | $213.21 | 2025 | Bimzelx |
| Genzyme Corporation | $207.76 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $204.38 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $202.79 | 2024-2025 | Cobenfy |
| Paratek Pharmaceuticals, INC. | $182.22 | 2022-2025 | Nuzyra |
| Vanda Pharmaceuticals INC. | $155.34 | 2024-2025 | Fanapt, Hetlioz |
| Avadel Cns Pharmaceuticals, LLC | $138.94 | 2025 | Lumryz |
| Lundbeck LLC | $125.25 | 2024-2025 | Rexulti |
| Pharming Healthcare, INC. | $124.95 | 2024 | Ruconest |
| Xeris Pharmaceuticals, INC. | $121.06 | 2021-2025 | Recorlev, Keveyis |
| Grifols USA, LLC | $111.73 | 2021-2024 | Prolastin-C Liquid |
| Nestle Healthcare Nutrition INC. | $97.78 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.92 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $88.83 | 2019-2020 | |
| Almatica Pharma LLC | $84.24 | 2023-2025 | Loreev Xr, Teriparatide |
| Eisai INC. | $79.45 | 2020-2021 | |
| Exact Sciences Corporation | $71.64 | 2023-2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $65.22 | 2023 | Belbuca, Xtampza |
| Braeburn INC. | $61.04 | 2023-2024 | Brixadi |
| Sumitomo Pharma America, INC. | $60.43 | 2024-2025 | Gemtesa |
| Acerus Pharmaceuticals Corporation | $59.65 | 2021 | |
| Clarus Therapeutics INC. | $52.96 | 2021 | |
| Lucid Diagnostics INC. | $49.30 | 2023 | |
| Sanofi-Aventis U.S. LLC | $45.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $43.12 | 2022-2023 | Quviviq |
| Neurelis, INC. | $40.88 | 2023 | Valtoco |
| Amarin Pharma, INC. | $40.16 | 2019-2021 | |
| Phadia US INC. | $37.64 | 2021-2025 | Immunocap |
| Aytu Biopharma, INC. | $36.92 | 2020 | |
| Tolmar, INC. | $34.29 | 2024 | |
| Scilex Pharmaceuticals INC. | $24.57 | 2024 | |
| Si-Bone, INC. | $16.53 | 2024 | |
| Arbor Pharmaceuticals, INC. | $16.22 | 2019 | |
| Tms Neurohealth Centers INC. | $14.49 | 2025 | Tms Neurohealth Centers INC. |
| Tris Pharma INC | $14.43 | 2019 | |
| Strongbridge US INC. | $13.20 | 2020 | |
| Hologic Sales and Service, LLC | $13.18 | 2021 | |
| Antares Pharma, INC. | $11.08 | 2019 | |
| Evoke Pharma, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.